RecruitingNot ApplicableNCT03286335
Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
Sponsor
Massachusetts General Hospital
Enrollment
100 participants
Start Date
Sep 26, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
This research study is studying Proton Radiation as a possible treatment for brain tumor. The radiation involved in this study is: -Proton Radiation
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is tracking tumor control, quality of life, and side effects in adults with brain tumors (including both benign and low-grade tumors) who are treated with proton radiation therapy — a highly precise type of radiation that delivers energy directly to the tumor while sparing nearby healthy brain tissue.
**You may be eligible if...**
- You are 18 or older with a brain tumor that requires radiation treatment (common types include low-grade glioma, pituitary adenoma, acoustic neuroma, and meningioma, among others)
- You are recommended for proton radiation therapy by your medical team
- You are in reasonable health (Karnofsky score of 60 or above) and have a life expectancy of at least 6 months
- You can speak and understand English
**You may NOT be eligible if...**
- You have an uncontrolled active infection, heart problems, or a psychiatric condition that would affect your ability to follow the study
- You are pregnant or breastfeeding
- You have had another cancer within the last 3 years (with some exceptions for very early skin cancers)
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
RADIATIONProton Radiation
Radiation treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03286335
Related Trials
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
NCT055881411 location
Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders
NCT043227342 locations
Cognitive Training in the Virtual Reality Setting With Children Undergoing Radiotherapy for Brain Tumors
NCT059470451 location
C-SMART vs BE Well for Patients With Brain Tumors
NCT072245031 location
Non-invasive Glioma Characterization Through Molecular Imaging
NCT036841091 location